Professor Michelle Lockley
Telephone:
Email:
Location:
- University College Hospital
GMC/GDC number:
4443557
Professional background
Professor Lockley is a medical oncologist, specialising in the treatment and clinical investigation of ovarian cancer. She completed her PhD at the Barts Cancer Institute in 2008 and subsequently held a NIHR Clinical Lectureship at the University of Cambridge. She was appointed as a consultant in 2009.
Prof. Lockley held Cancer Research UK (CRUK) Clinician Scientist and CRUK Advanced Clinician Scientist Fellowships continually between 2011–2021 and became Professor of Medical Oncology at Queen Mary University of London in 2022.
Research interests
Her clinical practice and research programme both focus on ovarian cancer. High grade serous cancer (HGSC) is the most common subtype of ovarian cancer. This disease is initially very responsive to platinum and taxane chemotherapy but more than 70% patients develop chemotherapy resistance and the disease becomes incurable. PARP inhibitors are increasingly used in the treatment of ovarian cancer but resistance to these drugs is common and optimal duration of therapy is largely unknown. Circumventing drug resistance is therefore a major unmet clinical need.
Prof. Lockley leads a laboratory group at Barts Cancer Institute, Queen Mary University of London. Her lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to drug therapy. One such approach is called Adaptive Therapy (AT). AT is a novel treatment paradigm in which drug dose is tailored to the evolution of chemotherapy resistance in individual patients over time. We have successfully translated our research findings investigating AT to the ACTOv clinical trial (Adaptive ChemoTherapy in Ovarian cancer) that will recruit patients from 9 UK sites beginning in 2023.
She also has a special interest in rare gynaecological cancers, particularly ovarian germ cell tumours. She is a member of the NCRI early onset working party and Vice Chair of the Malignant Germ cell tumour International Consortium (MaGIC) where she is co-leading development of the next international trial for poor risk germ cell tumours.
Publications
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H, McNeish IA, Huang W, Maniati E, Graham TA, Lockley M. Gynecol Oncol. 2022 Jul 30:S0090-8258(22)00511-X. doi: 10.1016/j.ygyno.2022.07.027.
Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS.Eur J Cancer. 2022 Sep;173:59-70. doi: 10.1016/ j.ejca.2022.06.006. Epub 2022 Jul 18.PMID: 35863107 Review.
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. Cheng Z, Mirza H, Ennis DP, Smith P, Morrill Gavarró L, Sokota C, Giannone G, Goranova T, Bradley T, Piskorz A, Lockley M; BriTROC-1 Investigators, Kaur B, Singh N, Tookman LA, Krell J, McDermott J, Macintyre G, Markowetz F, Brenton JD, McNeish IA.Clin Cancer Res. 2022 Jul 1;28(13):2911-2922. doi: 10.1158/1078-0432.CCR-21-1643.PMID: 35398881
LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations. Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham TA. iScience. 2021 Jul 21;24(8):102889. pp 1-22, doi: 10.1016/j.isci.2021.102889. eCollection 2021 Aug 20.
Chloroxine Overrides DNA Damage Tolerance to Restore Platinum Sensitivity in High-grade Serous Ovarian Cancer. Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA and Lockley M Cell Death and Disease. 2021 Apr 14;12(4):395. pp 1-14, doi: 10.1038/s41419-021-03665-0
The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A, Barrett T, Alexander S, Rudman S, Lockley M, Berney D, Sahdev A. Br J Cancer. 2021 Jan;124(2):368-374.
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker SJ, Ledermann J, Berney DM, Shamash J, Banerjee S, Stoneham S, Lockley M. Eur J Cancer. 2019 May;113:19-27. doi: 10.1016/j.ejca.2019.03.001. Epub 2019 Apr 4.
Copy number signatures and mutational processes in ovarian carcinoma. Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD. Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.
Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight MM, Balkwill FR. Cancer Discov. 2018 Mar;8(3):304-319. doi: 10.1158/2159-8290.CD-17-0284. Epub 2017 Dec 1.